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I am very happy to write my opinion regarding Dr.
Oostrom’s paper. 
First of all, I agree with Dr. Oostrom’s shortened
BRCA counselling protocol. Actually, in my clinical
practice,  I have  already  adopted  the  shortened
protocol and usually two sessions are enough for
non-mutation carriers. Although my experience in
genetic counselling is not that long, I hardly encounter
patients with psychological distress that need additional
counselling sessions. 
There are some reasons for the successful adoption
of a shortened BRCA counselling protocol for patients
without psychological problems in Korea. First, the
incidence of breast cancer in Korea is lower than that
of Western countries (1 in 40 women will develop
breast cancer by the age of 70 years). Therefore,
women are less afraid of breast cancer compared to
those in Western countries. 
Second, most of the BRCA testing is not initiated
by the patients but by their doctors. In Korea, the history
of the BRCA testing is quite short and hereditary breast
cancer is not well recognised by the public. So, most
of the counsellees are not aware of the impact of BRCA
mutation until the end of their first counselling session.
Third, there is no genetic session counselling fee in
Korea. Practically, therefore, it is better to adopt
a shortened counselling protocol if there are no
elevated distress levels and a low prevalence of mental
health problems. 
The  mutation  carriers,  however,  might  need
psychological support to cope with the breast and
ovarian  cancer  risk  for  family  members  and  for
themselves. Although we can adopt the shortened
protocol for non-mutation carriers, we should provide
an opportunity for additional counselling sessions for
BRCA mutation carriers. 
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